Advancement in Technology Promotes Sepsis Diagnostic…

The global sepsis diagnostic market size is expected to reach a value of USD 1.1 billion by 2027, expanding at a CAGR of 9.4%, according to a new report by Grand View Research, Inc. High prevalence of sepsis, introduction of technologically advanced medical examination systems and increasing government initiatives is expected to propel market growth over the forecast period.

The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.

According to CDC estimates, every year more than 1.7 million adults in U.S. suffer from sepsis, which leads to around 270,000 deaths. Furthermore, according to the report published by OECD in 2018, every year around 3.8 million patients suffer from hospital-acquired infections (HAIs) in acute care hospitals in European countries. High prevalence of HAIs in key regions is expected to significantly increase the demand for medical examination solutions, thereby fueling market growth over the forecast period.

To Request Sample Copy of this report, click the link:
https://www.grandviewresearch.com/industry-analysis/sepsis-diagnostics-market/request/rs1

Increasing regulatory approval and introduction of technologically advanced medical examination solutions for the life-threatening disease condition are expected to facilitate market growth over the forecast period. In May 2018, T2 Biosystems, Inc., a U.S.-based emerging medical examination solutions company received the U.S. FDA approval for its T2Bacteria Panel, intended for the detection of specific sepsis-causing bacterial pathogens in human whole blood specimens.
In April 2019, the Scottish Government in collaboration with Sepsis Research (originally called FEAT - The Fiona Elizabeth Agnew Trust) launched a Scotland-wide campaign to spread public awareness about the signs and symptoms of sepsis. Such initiatives to raise public awareness about the disease condition is expected to raise demand for its rapid medical examination solutions and support its market growth in the near future.

Further key findings from the study suggest:

• In 2019, the blood culture media segment has emerged as the largest revenue generating segment owing to the high adoption of culture media tests in laboratories for the diagnosis of septic poisoning
• Molecular diagnostics is anticipated to witness a lucrative CAGR over the forecast period owing to its high sensitivity, accuracy, and less turnaround time
• In 2019, bacterial sepsis contributed towards the largest revenue share among the pathogen segment owing to its high prevalence
• North America dominated the sepsis diagnostics market with the largest revenue share in 2019. High awareness, favorable reimbursement scenario, and presence of established players are facilitating the dominance of this region during the study period
• The Asia Pacific region is projected to witness a lucrative growth owing to increasing awareness about sepsis diagnosis and treatment in emerging economies such as India and China
• Some of the key players include bioMérieux SA; Beckman Coulter, Inc.; Becton, Dickinson and Company; Sysmex Corporation; F. Hoffmann-La Roche AG; and Thermo Fisher Scientific, Inc.

The global sepsis diagnostic market size was valued at USD 550.2 million in 2019 and is expected to witness attractive growth over the forecast period. Factors such as high prevalence of sepsis, increasing awareness, and introduction of technologically advanced diagnostic solutions are expected to significantly fuel market growth over the forecast period.

Sepsis is a severe medical condition caused by the overwhelming immune response to an infection. Recent studies have shown an increasing prevalence of this life-threatening disease across the globe. According to the data published by WHO in April 2018, sepsis affects more than 30 million people globally and leads to around 6 million deaths every year. The same source states that globally, around 3 million newborns and 1.2 million children suffer from this condition every year. Such high prevalence is anticipated to increase the demand for diagnostic solutions and drive market growth over the forecast period.

Have any Query? Ask our Experts:
https://www.grandviewresearch.com/inquiry/3575/ibb

Grand View Research has segmented the global sepsis diagnostics market on the basis of product, technology, pathogen, testing type, and region:
Sepsis Diagnostics Product Outlook (Revenue, USD Million, 2016 - 2027)

• Instruments
  • Microbiology
  • Molecular Diagnostics
  • Immunoassays
  • Flow Cytometry
• Blood Culture Media
  • Microbiology
  • Molecular Diagnostics
  • Immunoassays
  • Flow Cytometry
• Assay Kits and Reagents
  • Microbiology
  • Molecular Diagnostics
  • Immunoassays
  • Flow Cytometry
• Software
  • Microbiology
  • Molecular Diagnostics
  • Immunoassays
  • Flow Cytometry

Sepsis Diagnostics Technology Outlook (Revenue, USD Million, 2016 - 2027)

• Microbiology
• Molecular Diagnostics
• Immunoassays
• Flow Cytometry

Sepsis Diagnostics Pathogen Outlook (Revenue, USD Million, 2016 - 2027)

• Bacterial Sepsis
  • Gram-Positive Bacteria
  • Gram-Negative Bacteria
• Fungal Sepsis
• Others

Sepsis Diagnostics Testing Type Outlook (Revenue, USD Million, 2016 - 2027)

• Laboratory Testing
• PoC Testing

About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.